Demographic, clinical and lifestyle factors associated with high-intensity statin therapy in Australia: the AusDiab study

Karen Ho, Kris M. Jamsen, J. Simon Bell, Maarit Jaana Korhonen, Kevin P. Mc Namara, Dianna J. Magliano, Danny Liew, Taliesin E. Ryan-Atwood, Jonathan E. Shaw, Susan Luc, Jenni Ilomäki

Research output: Contribution to journalArticleResearchpeer-review

Abstract

Purpose: Clinical guidelines specify who should receive high-intensity statins; however, it is unclear how high-intensity statins are used in Australia. Our objective was to determine the demographic, clinical, and lifestyle factors associated with high-intensity statin therapy in Australia. Methods: Data from the Australian Diabetes, Obesity and Lifestyle study collected in 2011–2012 were analyzed. High-, moderate-, and low-intensity statins were defined as use of statins at doses demonstrated to reduce low-density lipoprotein cholesterol levels by > 50, 30–50, and < 30%, respectively. Logistic regression was used to estimate adjusted odd ratios (ORs) and 95% confidence intervals (CIs) for factors associated with high- versus low-to-moderate-intensity statin therapy. Results: Overall, 1108 (24%) study participants used a statin. Data on statin intensity were available for 1072 participants. The proportions of high-, moderate-, and low-intensity statin therapy were 32 (n = 341), 65 (n = 696), and 3% (n = 35), respectively. Overall, 51% of people with prior cardiovascular disease (CVD) used a high-intensity statin. In addition to prior CVD (OR = 3.34, 95% CI = 1.95–5.73), no (OR = 1.84, 95%CI 1.02–3.31) or insufficient physical activity (OR = 1.51, 95% CI = 1.01–2.25), obesity (OR = 1.87, 95% CI = 1.13–3.10), and consuming > 2 alcoholic drinks daily (OR = 1.66, 95% CI = 1.08–2.55) were associated with high versus low-to-moderate-intensity statin therapy. Conversely, age 65–74 vs. < 65 years was inversely associated with high-intensity statin therapy (OR = 0.62, 95% CI = 0.41–0.94). Conclusions: Prior CVD was the strongest factor associated with high-intensity statin therapy. Although the prevalence of CVD increases with age, older people were less likely to be treated with high-intensity statins.

Original languageEnglish
Pages (from-to)1493-1501
Number of pages9
JournalEuropean Journal of Clinical Pharmacology
Volume74
Issue number11
DOIs
Publication statusPublished - 1 Nov 2018

Keywords

  • Australia
  • Cardiovascular disease
  • Cholesterol
  • Epidemiology
  • HMG-CoA reductase inhibitors

Cite this

@article{e10780e7ab704c08b137f2d3d3299a7d,
title = "Demographic, clinical and lifestyle factors associated with high-intensity statin therapy in Australia: the AusDiab study",
abstract = "Purpose: Clinical guidelines specify who should receive high-intensity statins; however, it is unclear how high-intensity statins are used in Australia. Our objective was to determine the demographic, clinical, and lifestyle factors associated with high-intensity statin therapy in Australia. Methods: Data from the Australian Diabetes, Obesity and Lifestyle study collected in 2011–2012 were analyzed. High-, moderate-, and low-intensity statins were defined as use of statins at doses demonstrated to reduce low-density lipoprotein cholesterol levels by > 50, 30–50, and < 30{\%}, respectively. Logistic regression was used to estimate adjusted odd ratios (ORs) and 95{\%} confidence intervals (CIs) for factors associated with high- versus low-to-moderate-intensity statin therapy. Results: Overall, 1108 (24{\%}) study participants used a statin. Data on statin intensity were available for 1072 participants. The proportions of high-, moderate-, and low-intensity statin therapy were 32 (n = 341), 65 (n = 696), and 3{\%} (n = 35), respectively. Overall, 51{\%} of people with prior cardiovascular disease (CVD) used a high-intensity statin. In addition to prior CVD (OR = 3.34, 95{\%} CI = 1.95–5.73), no (OR = 1.84, 95{\%}CI 1.02–3.31) or insufficient physical activity (OR = 1.51, 95{\%} CI = 1.01–2.25), obesity (OR = 1.87, 95{\%} CI = 1.13–3.10), and consuming > 2 alcoholic drinks daily (OR = 1.66, 95{\%} CI = 1.08–2.55) were associated with high versus low-to-moderate-intensity statin therapy. Conversely, age 65–74 vs. < 65 years was inversely associated with high-intensity statin therapy (OR = 0.62, 95{\%} CI = 0.41–0.94). Conclusions: Prior CVD was the strongest factor associated with high-intensity statin therapy. Although the prevalence of CVD increases with age, older people were less likely to be treated with high-intensity statins.",
keywords = "Australia, Cardiovascular disease, Cholesterol, Epidemiology, HMG-CoA reductase inhibitors",
author = "Karen Ho and Jamsen, {Kris M.} and Bell, {J. Simon} and Korhonen, {Maarit Jaana} and {Mc Namara}, {Kevin P.} and Magliano, {Dianna J.} and Danny Liew and Ryan-Atwood, {Taliesin E.} and Shaw, {Jonathan E.} and Susan Luc and Jenni Ilom{\"a}ki",
year = "2018",
month = "11",
day = "1",
doi = "10.1007/s00228-018-2518-1",
language = "English",
volume = "74",
pages = "1493--1501",
journal = "European Journal of Clinical Pharmacology",
issn = "0031-6970",
publisher = "Springer-Verlag London Ltd.",
number = "11",

}

Demographic, clinical and lifestyle factors associated with high-intensity statin therapy in Australia : the AusDiab study. / Ho, Karen; Jamsen, Kris M.; Bell, J. Simon; Korhonen, Maarit Jaana; Mc Namara, Kevin P.; Magliano, Dianna J.; Liew, Danny; Ryan-Atwood, Taliesin E.; Shaw, Jonathan E.; Luc, Susan; Ilomäki, Jenni.

In: European Journal of Clinical Pharmacology, Vol. 74, No. 11, 01.11.2018, p. 1493-1501.

Research output: Contribution to journalArticleResearchpeer-review

TY - JOUR

T1 - Demographic, clinical and lifestyle factors associated with high-intensity statin therapy in Australia

T2 - the AusDiab study

AU - Ho, Karen

AU - Jamsen, Kris M.

AU - Bell, J. Simon

AU - Korhonen, Maarit Jaana

AU - Mc Namara, Kevin P.

AU - Magliano, Dianna J.

AU - Liew, Danny

AU - Ryan-Atwood, Taliesin E.

AU - Shaw, Jonathan E.

AU - Luc, Susan

AU - Ilomäki, Jenni

PY - 2018/11/1

Y1 - 2018/11/1

N2 - Purpose: Clinical guidelines specify who should receive high-intensity statins; however, it is unclear how high-intensity statins are used in Australia. Our objective was to determine the demographic, clinical, and lifestyle factors associated with high-intensity statin therapy in Australia. Methods: Data from the Australian Diabetes, Obesity and Lifestyle study collected in 2011–2012 were analyzed. High-, moderate-, and low-intensity statins were defined as use of statins at doses demonstrated to reduce low-density lipoprotein cholesterol levels by > 50, 30–50, and < 30%, respectively. Logistic regression was used to estimate adjusted odd ratios (ORs) and 95% confidence intervals (CIs) for factors associated with high- versus low-to-moderate-intensity statin therapy. Results: Overall, 1108 (24%) study participants used a statin. Data on statin intensity were available for 1072 participants. The proportions of high-, moderate-, and low-intensity statin therapy were 32 (n = 341), 65 (n = 696), and 3% (n = 35), respectively. Overall, 51% of people with prior cardiovascular disease (CVD) used a high-intensity statin. In addition to prior CVD (OR = 3.34, 95% CI = 1.95–5.73), no (OR = 1.84, 95%CI 1.02–3.31) or insufficient physical activity (OR = 1.51, 95% CI = 1.01–2.25), obesity (OR = 1.87, 95% CI = 1.13–3.10), and consuming > 2 alcoholic drinks daily (OR = 1.66, 95% CI = 1.08–2.55) were associated with high versus low-to-moderate-intensity statin therapy. Conversely, age 65–74 vs. < 65 years was inversely associated with high-intensity statin therapy (OR = 0.62, 95% CI = 0.41–0.94). Conclusions: Prior CVD was the strongest factor associated with high-intensity statin therapy. Although the prevalence of CVD increases with age, older people were less likely to be treated with high-intensity statins.

AB - Purpose: Clinical guidelines specify who should receive high-intensity statins; however, it is unclear how high-intensity statins are used in Australia. Our objective was to determine the demographic, clinical, and lifestyle factors associated with high-intensity statin therapy in Australia. Methods: Data from the Australian Diabetes, Obesity and Lifestyle study collected in 2011–2012 were analyzed. High-, moderate-, and low-intensity statins were defined as use of statins at doses demonstrated to reduce low-density lipoprotein cholesterol levels by > 50, 30–50, and < 30%, respectively. Logistic regression was used to estimate adjusted odd ratios (ORs) and 95% confidence intervals (CIs) for factors associated with high- versus low-to-moderate-intensity statin therapy. Results: Overall, 1108 (24%) study participants used a statin. Data on statin intensity were available for 1072 participants. The proportions of high-, moderate-, and low-intensity statin therapy were 32 (n = 341), 65 (n = 696), and 3% (n = 35), respectively. Overall, 51% of people with prior cardiovascular disease (CVD) used a high-intensity statin. In addition to prior CVD (OR = 3.34, 95% CI = 1.95–5.73), no (OR = 1.84, 95%CI 1.02–3.31) or insufficient physical activity (OR = 1.51, 95% CI = 1.01–2.25), obesity (OR = 1.87, 95% CI = 1.13–3.10), and consuming > 2 alcoholic drinks daily (OR = 1.66, 95% CI = 1.08–2.55) were associated with high versus low-to-moderate-intensity statin therapy. Conversely, age 65–74 vs. < 65 years was inversely associated with high-intensity statin therapy (OR = 0.62, 95% CI = 0.41–0.94). Conclusions: Prior CVD was the strongest factor associated with high-intensity statin therapy. Although the prevalence of CVD increases with age, older people were less likely to be treated with high-intensity statins.

KW - Australia

KW - Cardiovascular disease

KW - Cholesterol

KW - Epidemiology

KW - HMG-CoA reductase inhibitors

UR - http://www.scopus.com/inward/record.url?scp=85050292180&partnerID=8YFLogxK

U2 - 10.1007/s00228-018-2518-1

DO - 10.1007/s00228-018-2518-1

M3 - Article

VL - 74

SP - 1493

EP - 1501

JO - European Journal of Clinical Pharmacology

JF - European Journal of Clinical Pharmacology

SN - 0031-6970

IS - 11

ER -